what we do

Paxman as a company was born out of a husbandus desire to prevent his wife from suffering through the trauma
of chemotherapy-induced hair loss. Our founder and chairman Glenn Paxman used his knowledge and expertise in the refrigeration industry to pioneer a scalp cooling system that enables people going through chemotherapy treatment to maintain their hair.

The family mentality of caring and supporting those going through what can be traumatic treatment side effects is maintained to this day and has become a core value as Paxman continues to grow. We understand how important consistency, privacy and control are to a patient facing cancer.

Paxmans Scalp Cooling system has been clinically proven to help manage and reduce hair loss during chemotherapy and to support increased rates of hair regrowth. Chemotherapy-induced alopecia is the most feared side effect of treatment in over 75% of patients.

Biological investigations conducted by the Paxman Research & Innovation Centre found that there are multiple mechanisms of action which occur because of scalp cooling. The most commonly recognised is vasoconstriction reducing the amount of chemotherapy-infused blood flow to the scalp. It has been proven that it is likely that a combination of mechanisms renders scalp cooling effective.

The Paxman Scalp Cooling System comprises a compact refrigeration unit that circulates a specially formulated liquid coolant through a lightweight, medical-grade silicone cold cap, designed to reduce the scalp temperature.

The Cap is designed to be flexible ensuring close contact with the patientu2019s scalp, which is essential for the best possible hair retention outcomes. The Cap Cover, which is made of neoprene, insulates the inner Cap and helps to deliver a close and consistent fit for the patient.

As the leader in scalp cooling technology, there are over 5,000 Paxman Systems installed in over 65 markets internationally. One thousand of these systems are located in the U.K. covering 98% of private and National Health Service hospitals. Over 100,000 patients have been treated by Paxman globally.

Scalp cooling is the only clinically proven and effective method of preventing and managing chemotherapy-induced alopecia.

Studies have shown that scalp cooling efficacy varies based on drug regimen, but as an average across the board, patients have a 50% chance of retaining half of their hair with scalp cooling.

Clinical data

Clinical data has also proven that scalp cooling not only helps to reduce chemotherapy-induced hair loss, but it also protects the hair follicle, increasing the rate of hair recovery and regrowth, even if significant hair loss is sustained. Faster and healthier hair regrowth has such an impact on the patient population, that many are now heading into treatment citing faster regrowth as the primary motivation for choosing scalp cooling.

Retaining hair and ensuring quicker regrowth provides scalp cooling patients with a sense of control over their treatment and can bring back some privacy and normality to their lives during cancer treatment.

There has been extensive clinical research conducted on scalp cooling internationally.

Visit the Scalp Cooling Study Library for a wide range of clinical data on efficacy, safety and more.

Paxman provides support and guidance to patients at every stage of the scalp cooling process u2013 from consideration, through treatment and beyond their final chemotherapy treatment. Patients are provided with a wealth of information in the form of supportive patient education materials and a comprehensive website offering in depth u2018How-tou2019 videos, ensuring the patient can go into treatment educated and prepared.

Investing in cryotherapy initiatives, Paxman has a strong R&D department that works closely with several global organisations and institutions to ensure the accelerated advancement of principals and ideas. The work developed through these partnerships has been highly praised.

Research Excellence Framework

Development of devices, cooling caps, scalp cooling treatment and efficacy has always been a central commitment for Paxman. The business has long-standing collaborative relationships with several Universities including the University of Huddersfield, the National University of Singapore, Kingu2019s College London and the University of Leeds.

The Paxman Research & Innovation Centre, in conjunction with the University of Huddersfield, produced the first ever research paper on cellular response to cold protection from chemotherapy, showing that cold exposure to the hair follicle helps to reduce hair loss.

The National University of Singapore

Work with The National University of Singapore has resulted in a new approach to combinatorial treatment of chemotherapy-induced peripheral neuropathy. Nerve damage through chemotherapy is a well-documented side effect of cancer treatment and one that Paxman are committed to providing a solution for. The medical device that has been developed is in the final stages of clinical trialling.

Design development

Product design research is currently ongoing with the University of Huddersfield, which was awarded 4 stars by the Research Excellence Framework. A new cooling cap and cover design features the use of bespoke recyclable and sustainable materials with an innovative manufacturing approach to achieve improved comfort and fit.

Current biological research is developing a topical agent that will enhance the effect of scalp cooling providing added resistance to chemotherapy at the hair follicle, with the intention of vastly improving scalp cooling efficacy.